These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17436714

  • 1. [The clinical and pharmacoeconomic aspects of gemifloxacin(corrected) use in the patients with extra-hospital pneumonia in stationary conditions].
    Zaĭtsev AA, Sinopal'nikova AI.
    Voen Med Zh; 2007 Jan; 328(1):44-51. PubMed ID: 17436714
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [Abstract] [Full Text] [Related]

  • 3. Gemifloxacin (factive).
    Med Lett Drugs Ther; 2004 Sep 27; 46(1192):78-9. PubMed ID: 15452464
    [No Abstract] [Full Text] [Related]

  • 4. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Sep 27; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 5. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM, Tillotson G.
    Int J Antimicrob Agents; 2008 Apr 27; 31(4):299-306. PubMed ID: 18276120
    [Abstract] [Full Text] [Related]

  • 6. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS.
    Expert Rev Anti Infect Ther; 2008 Aug 27; 6(4):405-18. PubMed ID: 18662107
    [Abstract] [Full Text] [Related]

  • 7. Gemifloxacin for community-acquired pneumonia.
    Lode HM, Schmidt-Ionas M, Stahlmann R.
    Expert Opin Investig Drugs; 2008 May 27; 17(5):779-86. PubMed ID: 18447602
    [Abstract] [Full Text] [Related]

  • 8. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul 27; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 9. [Clinical and pharmacoeconomic perspective use of amoxicillin/sulbactam in the treatment of extra-hospital pneumonia].
    Sinopal'nikov AI, Zaĭtsev AA.
    Voen Med Zh; 2006 Nov 27; 327(11):42-5. PubMed ID: 17300060
    [No Abstract] [Full Text] [Related]

  • 10. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.
    Jivcu C, Gotfried M.
    Int J Chron Obstruct Pulmon Dis; 2009 Nov 27; 4():291-300. PubMed ID: 19684863
    [Abstract] [Full Text] [Related]

  • 11. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
    Starodubtseva OI, Vakhrushev IaM.
    Probl Tuberk Bolezn Legk; 2009 Nov 27; (6):28-9. PubMed ID: 19642570
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI.
    Am J Manag Care; 2004 Oct 27; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract] [Full Text] [Related]

  • 13. [Pharmacoeconomic efficiency of sparfloxacin use in empiric therapy of community-acquired pneumonia].
    Lazareva NB.
    Antibiot Khimioter; 2007 Oct 27; 52(7-8):53-7. PubMed ID: 18986025
    [No Abstract] [Full Text] [Related]

  • 14. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
    Kulidzhanov AIu, Sirotko II, Koriakin PM, Korchazhkin VS.
    Voen Med Zh; 2001 Jan 27; 322(1):50-2. PubMed ID: 11219929
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
    Rakov AL, Grinevich VB, Kriukov AE, Bogdanov IV, Rysev AV, Zakharchenko MM, Dobrenko VA, Gubonina IV.
    Voen Med Zh; 2006 Apr 27; 327(4):15-22. PubMed ID: 16784101
    [No Abstract] [Full Text] [Related]

  • 16. [Intractable pediatric infectious disease: examining the ability of a new drug, tosufloxacin tosilate hydrate for pediatric].
    Sunakawa K.
    Jpn J Antibiot; 2010 Dec 27; 63(6):387-99. PubMed ID: 21425593
    [No Abstract] [Full Text] [Related]

  • 17. Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.
    Ross JE, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Mar 27; 51(3):219-21. PubMed ID: 15766610
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec 27; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.